Cardiac Magnetic Resonance Monitoring of Immune Checkpoint Inhibitor-related Cardiotoxicity

Inclusion Criteria: * 1\. Female patients aged 18 to 75 years, diagnosed with gynecological malignancies through histology or cytology. * 2\. Patients who are preparing for monotherapy or combination therapy with ICIs. * 3\. Voluntary signing of informed consent form. * 4\. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * 5\. Expected survival of at least 6 months. Exclusion Criteria: * 1\. Previously received ICIs treatment. * 2\. With allergies or contraindications to ICIs. * 3\. Confirmed to be brain metastasis. * 4\. Patients who have major surgery within 4 weeks prior to or following the screening period. * 5\. Patients who have received systemic corticosteroids (at a dose equivalent to \>10 mg prednisone per day) or other immunosuppressive medications within 14 days prior to enrollment or during the study period; however, the following situations are allowed for inclusion: 1. the use of topical or inhaled corticosteroids is permitted; 2. short-term (≤7 days) use of corticosteroids for prevention or treatment of non-autoimmune diseases is allowed. * 6\. Left ventricular ejection fraction (LVEF) ≤50%, or New York Heart Association functional classification (NYHA) ≥III. * 7\. Coronary heart disease, cardiomyopathy, congenital heart disease, valvular heart disease and pericardial diseases with confirmed diagnosis. * 8\. Lack of autonomous capacity, or a documented history of mental disease. * 9\. MRI contraindications: Pacemakers, neurostimulators, artificial metal heart valves, arterial aneurysm clips, intraocular metallic foreign bodies, inner ear implants, metal prostheses, metal limbs, metal joints, and any other metallic implants or foreign objects; severe hyperthermia patients; claustrophobia; severe respiratory conditions that prevent breath-holding.